Insider Selling: Bausch Health Cos (NYSE:BHC) Insider Sells 36,827 Shares of Stock

Bausch Health Cos Inc. (NYSE:BHC) insider Aimee Lenar sold 36,827 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the sale, the insider owned 334,853 shares in the company, valued at approximately $2,354,016.59. The trade was a 9.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bausch Health Cos Stock Down 0.7%

NYSE BHC traded down $0.05 on Thursday, reaching $6.84. The company had a trading volume of 1,904,329 shares, compared to its average volume of 2,545,744. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of -2.31 and a beta of 0.38. The company has a debt-to-equity ratio of 54.68, a quick ratio of 1.08 and a current ratio of 1.44. Bausch Health Cos Inc. has a 1-year low of $4.33 and a 1-year high of $8.00. The company’s fifty day moving average is $5.30 and its 200-day moving average is $5.45.

Bausch Health Cos (NYSE:BHC) last released its earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.30. The firm had revenue of $2.83 billion during the quarter, compared to analysts’ expectations of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. On average, research analysts forecast that Bausch Health Cos Inc. will post 4.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Weiss Ratings raised Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Zacks Research downgraded shares of Bausch Health Cos from a “hold” rating to a “strong sell” rating in a report on Friday, July 24th. Wall Street Zen raised shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Royal Bank Of Canada reduced their target price on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a report on Monday, April 27th. Finally, Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bausch Health Cos has a consensus rating of “Reduce” and an average target price of $8.00.

Institutional Trading of Bausch Health Cos

Several institutional investors and hedge funds have recently bought and sold shares of BHC. Tacita Capital Inc bought a new position in Bausch Health Cos in the second quarter valued at approximately $29,000. Caption Management LLC boosted its holdings in shares of Bausch Health Cos by 101.1% in the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after buying an additional 405,789 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Bausch Health Cos by 12,589.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock valued at $34,000 after buying an additional 4,910 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Bausch Health Cos by 6,661.2% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after buying an additional 5,329 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after buying an additional 3,106 shares in the last quarter. Institutional investors own 78.65% of the company’s stock.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.